A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.
about
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolismOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolismOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosisXimelagatran: direct thrombin inhibitorNew anticoagulants for the prevention and treatment of venous thromboembolismAnticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatranEffectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysisDirect thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillationChoosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trialsOral direct thrombin inhibitors in clinical development.Direct thrombin inhibitors for anticoagulation.Venous thromboembolism and malignancy.Ximelagatran: light at the end of the tunnel or the next tunnel?Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management.Ximelagatran: a new antithrombotic option in atrial fibrillation.Ximelagatran: an oral direct thrombin inhibitor.Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinEmerging strategies for treatment of venous thromboembolism.Ximelagatran for stroke prevention in atrial fibrillation.A preliminary assessment of the critical differences between novel oral anticoagulants currently in development.The status of new anticoagulants.Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile.Initial and long-term treatment of deep venous thrombosis: recent clinical trials and their impact on patient management.The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol.No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.Ximelagatran--recent comparisons with warfarin.Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study.New oral anticoagulants: an emergency department overview.
P2860
Q24187205-9B21386F-4B60-4D4E-AB81-E781F036204DQ24200864-8DBF66C4-82F1-4590-8BB4-2F2F40EC701EQ24200867-6EF192F0-6C68-402D-8C88-9E773B7AC2B4Q24681333-F672A614-2CC7-4B69-8FEB-9545A04F109BQ24681351-9C683D1D-33E9-4A48-A6EA-EC0AA713EDD6Q24807132-FDA0897D-DF8C-4D79-B64F-251B6E55F59CQ27027477-9B9428E5-BE38-4300-BA61-3FD1D2912610Q28176666-EF00863D-8AC3-4D80-9C94-4847ED2DBF5CQ33372266-B963B4A5-5149-413A-9167-F2FBA63A8F1EQ34311567-E0CCC8E8-6A17-4DB1-BF63-D0DC63808548Q35219373-AC6F5201-D65E-4BB3-9C95-FEA129BE8F1FQ35638059-7F9D8797-D2FE-41BF-91A8-97F7012AF99CQ35728779-26AED232-D826-46B3-934F-6F1A58A4AD6CQ35843153-6A9019A3-3359-4B48-ADEC-911987D88744Q35878355-66FB2E28-2001-4B06-B8C2-A359B7C3F9FBQ35892171-241ABD63-D8D5-4415-B86C-FFB11D3C553EQ35895188-7D186D9B-8D01-46FC-AC30-00646466BB2FQ35996015-F9CAF7BE-3B8E-43A2-9BEC-8E5FCEE3CBE4Q35996023-D6EAA5DD-694A-40B8-B279-AA5F154B8CAAQ36042279-D8DA080C-874E-4F70-A5E7-E628857E9FF3Q36066023-73101BD5-96CA-4846-8DFA-692CC0AE181AQ36216784-7732AD58-B4AC-49BA-A118-69AA942D8B44Q36229356-562BDBD4-1BDD-44D7-B4C6-9CB97992017AQ36520745-C496083F-64B0-40FA-A857-8F94564B0DA7Q36884659-2FF94670-2E4B-4701-A3B4-F71212A0A5E7Q36905848-4BA0841A-9A63-499A-BE16-B72402CC4530Q38081938-719E5E2E-D864-4F76-92A1-7BB251A02941Q44820370-EA6A1B76-3753-44A5-8660-33216182DF13Q45001580-77FD48BA-6F94-4394-B3D9-555943CF8F34Q45022899-E5C386DC-5D2F-4C81-AC23-673DA430CE89Q46688989-904E00F8-653C-4486-86A2-9AB73EFA5C19Q47328874-E7402A18-08F1-4086-953E-5149C77172FAQ54610809-C7D97186-95E7-40FC-9B0B-1B21A47D20AA
P2860
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A randomized, controlled, dose ...... eep vein thrombosis: THRIVE I.
@ast
A randomized, controlled, dose ...... eep vein thrombosis: THRIVE I.
@en
type
label
A randomized, controlled, dose ...... eep vein thrombosis: THRIVE I.
@ast
A randomized, controlled, dose ...... eep vein thrombosis: THRIVE I.
@en
prefLabel
A randomized, controlled, dose ...... eep vein thrombosis: THRIVE I.
@ast
A randomized, controlled, dose ...... eep vein thrombosis: THRIVE I.
@en
P2093
P2860
P1476
A randomized, controlled, dose ...... deep vein thrombosis: THRIVE I
@en
P2093
D Gustafsson
K Wåhlander
Thrive Investigators
P2860
P356
10.1046/J.1538-7836.2003.00034.X
P577
2003-01-01T00:00:00Z